Adrian Rawcliffe, CEO of Adaptimmune at EUBIO22 (Photographer: Rachel Kiki)
November 8, 2022 11:02 AM EST
People

Adap­ti­m­mune trims pipeline, un­veils plans to lay off 25%+ of em­ploy­ees amid sweet­ened ES­MO da­ta

Paul Schloesser

Associate Editor

Adap­ti­m­mune has a bit­ter pill to swal­low af­ter GSK axed its part­ner­ship in late Oc­to­ber, com­ing in the form of a re­or­ga­ni­za­tion and bud­get cuts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times